Financial health
- The company is unprofitable; at its current free-cash-flow burn it has roughly 1.5 years of cash runway.
10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | -$230M | — | — | -146.1% | -65.4% | -$137M | — | $210M |
| 2024 | — | -$176M | — | — | -117.2% | -52.5% | -$118M | — | $168M |
| 2023 | — | -$260M | — | — | -98.0% | -54.3% | -$196M | — | $286M |
| 2022 | — | -$334M | — | — | -76.5% | -50.1% | -$243M | — | $190M |
| 2021 | — | -$267M | — | — | -40.3% | -29.5% | -$199M | — | $732M |
| 2020 | — | -$133M | — | — | -15.5% | -12.5% | -$87M | — | $944M |
| 2019 | — | -$47M | — | — | -13.7% | -13.2% | -$40M | — | $212M |
| 2018 | — | -$41M | — | — | -47.7% | -45.0% | -$29M | — | $88M |
| 2017 | — | -$28M | — | — | 40.6% | -861.2% | -$18M | — | $1M |
| 2016 | — | -$17M | — | — | 41.7% | — | -$17M | — | $10M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$66M | — | — | -107.4% | -25.6% | -$47M | — | $126M |
| Mar '26 | — | -$58M | — | — | -51.9% | -19.0% | -$41M | — | $170M |
| Dec '25 | — | -$57M | — | — | -36.0% | -16.1% | -$39M | — | $210M |
| Sep '25 | — | -$61M | — | — | -259.4% | -28.2% | -$33M | — | $72M |
| Jun '25 | — | -$54M | — | — | -77.3% | -21.2% | -$35M | — | $104M |
| Mar '25 | — | -$57M | — | — | -52.8% | -19.3% | -$29M | — | $139M |
| Dec '24 | — | -$44M | — | — | -29.3% | -13.1% | -$30M | — | $168M |
| Sep '24 | — | -$44M | — | — | -23.7% | -11.8% | -$21M | — | $198M |
| Jun '24 | — | -$45M | — | — | -21.0% | -11.2% | -$27M | — | $219M |
| Mar '24 | — | -$43M | — | — | -17.8% | -9.9% | -$40M | — | $246M |
| Dec '23 | — | -$60M | — | — | -22.4% | -12.4% | -$60M | — | $286M |
| Sep '23 | — | -$50M | — | — | -16.5% | -9.1% | -$33M | — | $346M |
| Jun '23 | — | -$80M | — | — | -23.7% | -13.6% | -$43M | — | $379M |
| Mar '23 | — | -$71M | — | — | -18.0% | -11.1% | -$59M | — | $317M |
| Dec '22 | — | -$70M | — | — | -16.2% | -10.6% | -$58M | — | $190M |
| Sep '22 | — | -$77M | — | — | -16.1% | -10.6% | -$61M | — | $178M |
| Jun '22 | — | -$91M | — | — | -17.1% | -11.6% | -$63M | — | $173M |
| Mar '22 | — | -$96M | — | — | -16.0% | -11.3% | -$61M | — | $672M |
| Dec '21 | — | -$93M | — | — | -14.0% | -10.3% | -$67M | — | $732M |
| Sep '21 | — | -$68M | — | — | -9.3% | -7.0% | -$57M | — | $799M |
See the revenue and net-income charts above for Kodiak Sciences Inc.'s multi-year trend.
As of FY2025, Kodiak Sciences Inc. reported — of total debt against $210M of cash.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.